These authors contributed equally to this study.
Article first published online: 9 DEC 2011
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 226, Issue 3, pages 427–441, February 2012
How to Cite
Duprez, R., Wilkerson, P. M., Lacroix-Triki, M., Lambros, M. B., MacKay, A., Hern, R. A., Gauthier, A., Pawar, V., Colombo, P.-E., Daley, F., Natrajan, R., Ward, E., MacGrogan, G., Arbion, F., Michenet, P., Weigelt, B., Vincent-Salomon, A. and Reis-Filho, J. S. (2012), Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J. Pathol., 226: 427–441. doi: 10.1002/path.3032
No conflicts of interest were declared.
Microarray comparative genomic hybridization data, the analysis history, script and code are available at: http://rock.icr.ac.uk/collaborations/ Mackay/Papillary.aCGH/
- Issue published online: 16 JAN 2012
- Article first published online: 9 DEC 2011
- Accepted manuscript online: 25 OCT 2011 04:52AM EST
- Manuscript Accepted: 12 OCT 2011
- Manuscript Revised: 21 SEP 2011
- Manuscript Received: 10 AUG 2011
|path_3032_sm_supportinginforsuppl.doc||108K||Supporting Information: Supplementary methods: details of power calculation, immunohistochemistry, chromogenic/fluorescence in situ hybridization, MassARRAY Sequenom Oncocarta, Sanger sequencing and microarray comparative genomic hybridization (aCGH)|
|path_3032_sm_supportinginforFS1.tif||522K||Supporting Information: Figure S1. Work flow for classification of papillary carcinomas and exclusion of in situ papillary carcinomas and neuroendocrine carcinomas.|
|path_3032_sm_supportinginforFS2.tif||3110K||Supporting Information: Figure S2. Amplifications of CCND1 and at 7q11.23 in two encapsulated low-grade papillary carcinomas.|
|path_3032_sm_supportinginforFS3.tif||1144K||Supporting Information: Figure S3. Subgroup analysis of the prevalence of gene copy number aberrations found in papillary carcinomas and in grade- and ER-matched IDC-NSTs according to histological grade.|
|path_3032_sm_supportinginforFS4.tif||1972K||Supporting Information: Figure S4. Unsupervised hierarchical clustering analysis of low-grade and grade I papillary carcinomas and grade- and ER-matched IDC-NSTs.|
|path_3032_sm_supportinginforFS5.tif||1378K||Supporting Information: Figure S5. Hierarchical clustering analysis of encapsulated, solid and invasive papillary carcinomas.|
|path_3032_sm_supportinginforTS1.pdf||86K||Supporting Information: Table S1. Summary of the antibodies, clones, dilutions, antigen retrieval methods, scoring systems and cut-offs used for immunohistochemical analysis.|
|path_3032_sm_supportinginforTS2.pdf||15K||Supporting Information: Table S2. Primers used for Sanger sequencing.|
|path_3032_sm_supportinginforTS3.doc||44K||Supporting Information: Table S3. Histopathological features of 63 papillary carcinomas of the breast.|
|path_3032_sm_supportinginforTS4.pdf||139K||Supporting Information: Table S4. Copy number gains and losses found in > 10% of papillary carcinomas of the breast**.|
|path_3032_sm_supportinginforTS5.pdf||58K||Supporting Information: Table S5. Recurrent (in two or more cases) amplifications found in 49 papillary carcinomas of the breast**.|
|path_3032_sm_supportinginforTS6.pdf||39K||Supporting Information: Table S6. Summary of genomic regions differentially gained or lost between papillary carcinomas and grade- and ER- matched IDC-NSTs (multi-Fisher's exact test p < 0.05)**.|
|path_3032_sm_supportinginforTS7.pdf||8K||Supporting Information: Table S7. Oncocarta panel mutation profiling of 49 papillary carcinomas of the breast and results of mutation validation by Sanger sequencing.|
|path_3032_sm_supportinginforTS8.pdf||12K||Supporting Information: Table S8. Histopathological and immunohistochemical features of 39 encapsulated, nine solid and 12 invasive papillary carcinomas of the breast.|
|path_3032_sm_supportinginforTS9.pdf||13K||Supporting Information: Table S9. Summary of genomic regions differentially gained or lost between encapsulated, solid and invasive papillary carcinomas of the breast**.|
|path_3032_sm_supportinginforTS10.doc||42K||Supporting Information: Table S10. Differences in the proportions of specific immunophenotypic and genomic features between papillary carcinomas and grade- and ER-matched IDC-NSTs at 80% power and a two-sided α of 1%.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.